Skip to main content
Evidence Snapshot

Egl nine homolog 1

CHEMBL5697 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T09:09:39Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5697
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Egl nine homolog 1 as ChEMBL target CHEMBL5697, mapped to UniProt Q9GZT9. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Egl nine homolog 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5697
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9GZT9
Egl nine homolog 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Egl nine homolog 1 matters

As of 2026-09-13

Egl nine homolog 1 is reviewed as Egl nine homolog 1 (UniProt Q9GZT9); Egl nine homolog 1 shows approved-linked disease relevance led by anemia (phenotype). 3 more disease programs remain visible in the same review block.; 2 linked drugs keep this evidence frame grounded.; the current evidence base includes 4 approved drugs, 2203 compounds, and 194 assays, with lead potency reaching pChEMBL 9.7.

Disease context
anemia (phenotype)

Egl nine homolog 1 shows approved-linked disease relevance led by anemia (phenotype). 3 more disease programs remain visible in the same review block. 2 linked drugs keep the rationale reviewable. 3 additional disease programs remain visible in the same card. Linked drugs include MOLIDUSTAT, VADADUSTAT.

Start review with anemia (phenotype) because it currently carries approved-linked support. Linked drugs include MOLIDUSTAT, VADADUSTAT. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 2 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 4 approved drugs, 2203 compounds, and 194 assays for this target. The dominant activity type is IC50. CHEMBL2043325 is the current potency anchor at pChEMBL 9.7.

Use CHEMBL2043325 as the tractability anchor when discussing potency (pChEMBL 9.7).

Activity source · ChEMBL 36 via Core Engine
4 approved pChEMBL 9.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Egl nine homolog 1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9GZT9, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why anemia (phenotype) is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2203
Total Compounds
194
Total Assays
4
Approved Drugs
IC50: 2860.0, KI: 5.0, EC50: 33.0, KD: 32.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL2043325
 9.7 IC50 —
No preferred name
CHEMBL2041193
 9.7 IC50 —
No preferred name
CHEMBL2041192
 9.7 IC50 —
No preferred name
CHEMBL2041190
 9.7 IC50 —
No preferred name
CHEMBL2041186
 9.7 IC50 —

Approved Drugs

Structure Compound First Approval
VADADUSTAT
CHEMBL3646221
 2023
DAPRODUSTAT
CHEMBL3544988
 2023
ROXADUSTAT
CHEMBL2338329
 2021
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T09:09:39Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5697